Interferon alfa-2b
Clinical data | |
---|---|
MedlinePlus | a690006 |
Pregnancy category |
|
Routes of administration | Subcutaneous, intramuscular |
ATC code | L03AB05 (WHO) |
Legal status | |
Legal status | |
Identifiers | |
IUPHAR/BPS | 8338 |
DrugBank | DB00105 |
ChemSpider | none |
ChEMBL | CHEMBL1201558 |
ECHA InfoCard | 100.208.165 |
(what is this?) (verify) |
Interferon alfa 2b is an antiviral drug originally discovered in the laboratory of Charles Weissmann at the University of Zurich, developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.
This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
Interferon alfa-2b products[1] | |||
---|---|---|---|
Product | Manufacturer | Features | Special uses |
Alpharona | Pharmaclon | ||
Intron-A/IntronA | Schering-Plough | ||
Realderon | Teva | ||
Reaferon EC | GNC Vector | ||
Reaferon EC-Lipint | Vector-Medica | liposomal | |
Infagel | Vector-Medica | ointment | |
Recolin | Vector-Medica | ||
Altevir | Bioprocess subsidiary | liquid, free of HSA | |
Kipferon | Alfarm | combination with IgM, IgA, IgG | |
Giaferon | A/S Vitafarma | ||
Genferon | Biocad | ||
Opthalamoferon | Firn-M | with dimedrol | eye infections |
See also
References
- ↑ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2.
External links
- Intron-A Summary of Product Characteristics
- Nagata S, Taira H, Hall A, et al. (Mar 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–20. doi:10.1038/284316a0. PMID 6987533.
This article is issued from Wikipedia - version of the 10/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.